がん遺伝子治療市場：治療法、適応症、用途別-2025年～2030年の世界予測

がん遺伝子治療市場は、2023年に22億米ドルと評価され、2024年には27億5,000万米ドルに達すると予測され、CAGR 20.22％で成長し、2030年には79億9,000万米ドルになると予測されています。

がん遺伝子治療は、人の細胞内の遺伝子命令を変化させることによって、がんの治療や予防を目指す画期的なアプローチです。この治療法には、機能不全に陥った遺伝子の健康なコピーを挿入したり、問題を引き起こしている遺伝子をノックアウトしたり、病気と闘うのに役立つ新しい遺伝子を導入したりする方法が含まれます。がん遺伝子治療の必要性は、個別化治療の選択肢を提供し、生存率を向上させ、従来のがん治療によく見られる全身的副作用を軽減する可能性にあります。その用途は多岐にわたり、主に精密腫瘍学、標的ドラッグデリバリー、再生医療が含まれます。エンドユーザーは病院、診療所、研究機関など多岐にわたり、この市場の広範な範囲を浮き彫りにしています。

がん遺伝子治療の市場成長を牽引しているのは、遺伝子工学技術の進歩、ゲノム研究への資金提供の増加、個別化医療に対する意識の高まりです。CRISPR-Cas9やその他の先進的な遺伝子編集ツールの開発により、潜在的な用途が拡大し、遺伝子治療がより身近で効果的なものとなっています。さらに、世界のがん罹患率の上昇と従来の治療法の限界が、革新的な解決策への需要を永続させています。しかし、高コスト、規制上のハードル、倫理的懸念、遺伝子治療の複雑な性質などの課題が、市場成長の障壁となっています。

研究開発投資の拡大、特にRNA誘導遺伝子編集とCAR T細胞療法の潜在的可能性に注目すれば、チャンスは十分にあります。バイオテクノロジー企業と学術機関との共同研究はイノベーションを促進します。市場関係者は認知度向上キャンペーンに注力し、ヘルスケアシステムとの強力な提携関係を構築して市場浸透を促進すべきです。また、企業は経済的障壁を克服するために、費用負担やリスク軽減戦略のためのパートナーシップを模索することもできます。しかし、持続的な成長のためには、潜在的な副作用への継続的な警戒と、倫理的な状況への慎重な対応が不可欠です。イノベーションを舵取り役として成長態勢にあるがん遺伝子治療市場は、継続的な調査、戦略的提携、強固な規制の枠組みによって、市場の潜在力を最大限に引き出す必要があります。

市場力学：急速に進化するがん遺伝子治療市場の主要市場インサイトを公開

がん遺伝子治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 増加するがんの有病率に対処するための治療オプションの必要性
  • がん研究活性化のための研究開発活動の活発化
  • がん治療法や遺伝子治療の開発に対する政府の支援
• 市場抑制要因
  • 副作用や製品回収のリスク
• 市場機会
  • 遺伝子治療がんセンターの世界的拡大
  • AIとMLの活用による細胞・遺伝子治療の加速化
• 市場の課題
  • 遺伝子治療の安全性に関する規制上の考慮事項

ポーターのファイブフォース：がん遺伝子治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん遺伝子治療市場における外部からの影響の把握

外部マクロ環境要因は、がん遺伝子治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん遺伝子治療市場における競合情勢の把握

がん遺伝子治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん遺伝子治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん遺伝子治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん遺伝子治療市場における成功への道筋を描く

がん遺伝子治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 増加するがんの罹患率に対処するための治療法の必要性
    • がん調査を刺激するための研究開発活動の強化
    • がん治療法や遺伝子治療の開発に対する政府の支援
  • 抑制要因
    • 有害な免疫反応や製品の回収のリスク
  • 機会
    • 遺伝子治療がんセンターの世界の拡大
    • AIとMLを活用して細胞・遺伝子治療を加速
  • 課題
    • 遺伝子治療の安全性に関する規制上の考慮事項
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん遺伝子治療市場：治療法別

• 遺伝子誘導免疫療法
• 遺伝子導入
• 腫瘍溶解性ウイルス療法

第7章 がん遺伝子治療市場：適応症別

• 乳がん
• 肝臓がん
• 肺がん
• 卵巣がん
• 膵臓がん
• 前立腺がん

第8章 がん遺伝子治療市場：最終用途別

• バイオ医薬品企業
• 診断センター
• 腫瘍学調査機関

第9章 南北アメリカのがん遺伝子治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のがん遺伝子治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがん遺伝子治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abeona Therapeutics Inc.
• Achieve Life Sciences, Inc.
• Adaptimmune Therapeutics PLC
• Alaunos Therapeutics Inc.
• Amgen, Inc.
• Bayer AG
• Biogen Inc.
• Bluebird Bio Inc.
• Bristol-Myers Squibb Company
• Candel Therapeutics
• Elevate Bio Inc.
• Genelux Corporation
• Gilead Sciences, Inc.
• GlaxoSmithKline Inc.
• ImmunityBio, Inc.
• Merck KGaA
• Precigen, Inc.
• Sarepta Therapeutics, Inc.
• Shanghai Sunway Biotech Co., Ltd.
• Sibiono GeneTech Co. Ltd.

LIST OF FIGURES

• FIGURE 1. CANCER GENE THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. CANCER GENE THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER GENE THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. CHINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. ITALY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. POLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. QATAR CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 149. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Gene Therapy Market was valued at USD 2.20 billion in 2023, expected to reach USD 2.75 billion in 2024, and is projected to grow at a CAGR of 20.22%, to USD 7.99 billion by 2030.

Cancer gene therapy is a revolutionary approach that aims to treat or prevent cancer by altering the genetic instructions within a person's cells. This therapy involves methods like inserting a healthy copy of a malfunctioning gene, knocking out a gene that's causing issues, or introducing a new gene to help fight the disease. The necessity for cancer gene therapy lies in its potential to provide personalized treatment options, improve survival rates, and reduce the systemic side effects commonly associated with traditional cancer treatments. Its applications are diverse and primarily include precision oncology, targeted drug delivery, and regenerative medicine. End-users span across hospitals, clinics, and research institutes, highlighting the vast scope of this market.

The market growth of cancer gene therapy is driven by advancements in genetic engineering technologies, increased funding for genomic research, and rising awareness regarding personalized medicine. The development of CRISPR-Cas9 and other advanced gene-editing tools has expanded potential applications, making gene therapy more accessible and effective. Moreover, the increasing incidence of cancer globally and the limitations of conventional treatments perpetuate the demand for innovative solutions. However, challenges, including high costs, regulatory hurdles, ethical concerns, and the complex nature of gene therapy, pose barriers to market growth.

Opportunities are ripe in expanding research and development investments, especially focusing on the latent potential of RNA-guided gene editing and CAR T-cell therapies. Collaborative efforts between biotech firms and academic institutions can foster innovation. Market players should focus on awareness campaigns and build strong alliances with healthcare systems to expedite market penetration. Businesses can also explore partnerships for cost-sharing and risk mitigation strategies to overcome financial barriers. However, ongoing vigilance for potential side effects and carefully navigating the ethical landscape is crucial for sustainable growth. The cancer gene therapy market is poised for growth, with innovation at the helm, necessitating continuous research, strategic alliances, and robust regulatory frameworks to maximize market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Gene Therapy Market

The Cancer Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Need for treatment options to tackle the growing prevalence of cancers
  • Increasing R&D activities to stimulate cancer research
  • Government support for the development of cancer treatment methods and gene therapy
• Market Restraints
  • Risk of adverse immune reaction and recall of products
• Market Opportunities
  • Expansion of gene therapy cancer centers worldwide
  • Utilization of AI and ML to accelerate cell and gene therapies
• Market Challenges
  • Regulatory considerations concerning the safety of gene therapy

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Gene Therapy Market

A detailed market share analysis in the Cancer Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Gene Therapy Market

A strategic analysis of the Cancer Gene Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Achieve Life Sciences, Inc., Adaptimmune Therapeutics PLC, Alaunos Therapeutics Inc., Amgen, Inc., Bayer AG, Biogen Inc., Bluebird Bio Inc., Bristol-Myers Squibb Company, Candel Therapeutics, Elevate Bio Inc., Genelux Corporation, Gilead Sciences, Inc., GlaxoSmithKline Inc., ImmunityBio, Inc., Merck KGaA, Precigen, Inc., Sarepta Therapeutics, Inc., Shanghai Sunway Biotech Co., Ltd., and Sibiono GeneTech Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapy, market is studied across Gene Induced Immunotherapy, Gene Transfer, and Oncolytic Virotherapy.
• Based on Indication, market is studied across Breast Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
• Based on End-Use, market is studied across Biopharmaceutical Companies, Diagnostic Centers, and Oncology Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Need for treatment options to tackle the growing prevalence of cancers
    • 5.1.1.2. Increasing R&D activities to stimulate cancer research
    • 5.1.1.3. Government support for the development of cancer treatment methods and gene therapy
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of adverse immune reaction and recall of products
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion of gene therapy cancer centers worldwide
    • 5.1.3.2. Utilization of AI and ML to accelerate cell and gene therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory considerations concerning the safety of gene therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Gene Therapy Market, by Therapy

• 6.1. Introduction
• 6.2. Gene Induced Immunotherapy
• 6.3. Gene Transfer
• 6.4. Oncolytic Virotherapy

7. Cancer Gene Therapy Market, by Indication

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Liver Cancer
• 7.4. Lung Cancer
• 7.5. Ovarian Cancer
• 7.6. Pancreatic Cancer
• 7.7. Prostate Cancer

8. Cancer Gene Therapy Market, by End-Use

• 8.1. Introduction
• 8.2. Biopharmaceutical Companies
• 8.3. Diagnostic Centers
• 8.4. Oncology Research Institutes

9. Americas Cancer Gene Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Gene Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Gene Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abeona Therapeutics Inc.
• 2. Achieve Life Sciences, Inc.
• 3. Adaptimmune Therapeutics PLC
• 4. Alaunos Therapeutics Inc.
• 5. Amgen, Inc.
• 6. Bayer AG
• 7. Biogen Inc.
• 8. Bluebird Bio Inc.
• 9. Bristol-Myers Squibb Company
• 10. Candel Therapeutics
• 11. Elevate Bio Inc.
• 12. Genelux Corporation
• 13. Gilead Sciences, Inc.
• 14. GlaxoSmithKline Inc.
• 15. ImmunityBio, Inc.
• 16. Merck KGaA
• 17. Precigen, Inc.
• 18. Sarepta Therapeutics, Inc.
• 19. Shanghai Sunway Biotech Co., Ltd.
• 20. Sibiono GeneTech Co. Ltd.